Dactolisib

Search with Google Search with Bing

Information
Drug Name
Dactolisib
Description
Entry(CIViC)
17
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
melanoma BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		D Predictive Supports Sensitivity/Response Somatic 2 26678033 Detail
head and neck cancer PIK3CA MUTATION PIK3CA MUTATION D Predictive Supports Sensitivity/Response Somatic 3 23619167 Detail
head and neck cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 1 25855885 Detail
head and neck cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 23619167 Detail
head and neck cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 23619167 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		D Predictive Supports Sensitivity/Response Somatic 3 23549875 Detail
lung adenocarcinoma PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19029981 Detail
colorectal cancer KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22392911 Detail
colorectal cancer KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 22392911 Detail
colorectal cancer NRAS p.Gln61Lys (p.Q61K)
( ENST00000369535.5 ) NRAS p.Gln61Lys (p.Q61K)
( ENST00000369535.5 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22392911 Detail
colorectal cancer KRAS p.Ala146Thr (p.A146T)
( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Ala146Thr (p.A146T)
( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22392911 Detail
colorectal cancer KRAS p.Ala146Val (p.A146V)
( ENST00000311936.8, ENST00000557334.6, ENST00000256078.10, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Ala146Val (p.A146V)
( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22392911 Detail
colorectal cancer KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 22392911 Detail
colorectal cancer KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22392911 Detail
lung non-small cell carcinoma KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 4 19029981 Detail
breast cancer AR OVEREXPRESSION
( ENST00000374690.9 ) AR OVEREXPRESSION
( ENST00000374690.9 ) 		D Predictive Supports Sensitivity/Response Somatic 3 24356815 Detail
colorectal cancer EIF4EBP1 PHOSPHORYLATION EIF4EBP1 PHOSPHORYLATION D Predictive Supports Resistance N/A 2 22262166 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
49 BRAF-mutant melanoma cell lines from patients n... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity true CIViC Evidence detail
Preclinical analysis of the predicitive value of P... PIK3CA PIK3CA MUTATION PIK3CA MUTATION Sensitivity true CIViC Evidence detail
Lentiviral transduction of PIK3CA H1047R mutation ... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Two head and neck cancer cell lines with PIK3CA H1... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Xenografts from one head and neck cancer cell line... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
In a mouse model of BRAF V600E colorectal cancer, ... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity true CIViC Evidence detail
Doxycycline dependent expression of the PIK3CA H10... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... KRAS KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... KRAS KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... NRAS NRAS p.Gln61Lys (p.Q61K)
( ENST00000369535.5 ) NRAS p.Gln61Lys (p.Q61K)
( ENST00000369535.5 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... KRAS KRAS p.Ala146Thr (p.A146T)
( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Ala146Thr (p.A146T)
( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... KRAS KRAS p.Ala146Val (p.A146V)
( ENST00000311936.8, ENST00000557334.6, ENST00000256078.10, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Ala146Val (p.A146V)
( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... KRAS KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
In 28 out of 40 (70%) metastatic colorectal cancer... KRAS KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
The use of NVP-BEZ235 in conjunction with ARRY-142... KRAS KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
In-vitro and xenograft studies of response of brea... AR AR OVEREXPRESSION
( ENST00000374690.9 ) AR OVEREXPRESSION
( ENST00000374690.9 ) 		Sensitivity true CIViC Evidence detail
12 CRC cell lines were evaluated. 40% of these wer... EIF4EBP1 EIF4EBP1 PHOSPHORYLATION EIF4EBP1 PHOSPHORYLATION Resitance or Non-Reponse true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT04668352 Completed Phase 3 A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly April 15, 2019 December 2, 2019
NCT04139915 Withdrawn Phase 3 Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly October 21, 2019 November 15, 2019